Navigation Links
Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches
Date:6/3/2015

NEW YORK, June 3, 2015 /PRNewswire/ -- Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches

Summary

GBI Research, a leading business intelligence provider, has released its latest research report, "Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches". The report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC).

Platinum-based chemotherapy, predominantly the chemotherapy regimen paclitaxel and carboplatin, is the standard of care for the treatment of platinum-sensitive OC (both first-line and recurrent). The initial treatment is quite effective, with the majority of patients entering remission. However, almost all relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies, as well as for more effective treatment options in platinum-resistant or refractory patients.

Although the current developmental pipeline is quite crowded, efficacy with these late-stage drugs has been poor, at best demonstrating minimal improvements in progression-free survival, but not overall survival. The promising investigational drug candidates olaparib and trebananib are expected to gain approval during the forecast period. However, even on approval they are not expected to have a high market penetration, owing to their minimal therapeutic efficacy and anticipated premium prices. As a result, the OC market in APAC is expected not be driven by new drug approvals, but primarily by inflation, and the increase in the prevalence of OC. Market revenue is forecast to rise at a limited CAGR of 5.1% to $417.6m in 2020.

Despite the poor clinical performance of current late-stage pipeline drugs, there is evidence of continued interest in the OC market, with a high number of drug candidates in the initial developmental pipeline, particularly at the Preclinical phase. There is a wide range of novel molecular targets distributed among these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in others in oncology.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for OC. It covers and includes -
- A brief introduction to OC, including the disease's pathogenesis, risk factors and diagnosis
- In-depth analysis of the drug combinations used in the treatment of OC, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
- A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
- Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
- Multi-scenario forecast market data to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
- Discussion of the drivers and barriers for market growth
- In-depth analysis of licensing and co-development deals involving drugs indicated in OC, including an outline of the key deals

Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to -
- Understand the efficacy and safety of the current monotherapies and drug combinations used in the treatment of OC, with in-depth analysis of the disease treatment algorithm
- Understand the key signaling pathways and molecular targets currently under investigation in OC drug development
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe the trends in clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for OC therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the OC therapeutics market

Read the full report: http://www.reportlinker.com/p02975928-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Celsion Corporation Announces ASCO 2015 GEN-1 Immunotherapy Phase 1b Results in Ovarian Cancer Presentation
2. Celsion Expands Clinical Development Plan for GEN-1 IL-12 Immunotherapy Program in Ovarian Cancer
3. Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers
4. WaferGen Bio-systems Announces Research Collaboration with Leading Canadian Laboratory in Breast and Ovarian Cancer Screening
5. Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer
6. VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer
7. CRLX101 Meets Primary Endpoint in Phase 2 Clinical Trial in Relapsed Ovarian Cancer
8. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
9. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
10. EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
11. Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... The National Comprehensive ... Chemotherapy Order Templates ( NCCN Templates ®) into the CureMD Oncology EHR to ... NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). , “The collaboration with CureMD ...
(Date:6/11/2019)... ... 2019 , ... SABRE , the leading brand in personal safety and ... showcase their latest and most innovative personal safety products, including the Mighty Discreet ... Summer Market 2019 (Booth #39158-UL), June 18-20 in Denver, CO. , SABRE’s ...
(Date:6/6/2019)... OAKLAND, Calif. (PRWEB) , ... June 06, 2019 , ... ... to further curtail US travel to Cuba. “This latest move is one more assault ... the island,” said Dr. Peter G. Bourne, Chair of MEDICC’s Board of Directors. ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... The University of Pittsburgh School of Health and ... Informatics (MSHI ) degree program to address the growing need for professionals who can ... of a larger effort for SHRS to bring more graduate degrees online. The Master ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... tissue fabrication, patient-matched models and surgical guides, and prosthetics and assistive devices—are ... patient care. Children with birth defects, soldiers with cranial injuries, conjoined twins, ...
(Date:6/12/2019)... ... June 12, 2019 , ... ... with caregivers and dementia patients to deteriorate. , Researchers from the University ... survey with professional caregivers who care for people who have dementia and experienced ...
(Date:6/12/2019)... (PRWEB) , ... June 12, 2019 , ... ... Miller, a quality assurance expert with more than 25 years of experience in ... Compliance for all classes of medical devices, has joined NDA Partners as an ...
(Date:6/12/2019)... ... 12, 2019 , ... In September of 2018, NVNA and Hospice (NVNA) partnered ... patient monitoring. Following its full-scale launch in March, NVNA has expanded its program with ... of 2019, NVNA has achieved an average all-cause hospital readmissions rate of 7.3% and ...
Breaking Medicine News(10 mins):